These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15154846)

  • 1. Inactivation of the bovine-spongiform-encephalopathy (BSE) agent by the acid and alkaline processes used in the manufacture of bone gelatine.
    Grobben AH; Steele PJ; Somerville RA; Taylor DM
    Biotechnol Appl Biochem; 2004 Jun; 39(Pt 3):329-38. PubMed ID: 15154846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gelatine production, the six steps to maximum safety.
    Schrieber R; Seybold U
    Dev Biol Stand; 1993; 80():195-8. PubMed ID: 8270109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of the BSE agent by the heat and pressure process for manufacturing gelatine.
    Grobben AH; Steele PJ; Somerville RA; Taylor DM; Schreuder BE
    Vet Rec; 2005 Sep; 157(10):277-81. PubMed ID: 16157568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of transmissible spongiform encephalopathy agents during the manufacture of dicalcium phosphate from bone.
    Grobben AH; Steele PJ; Somerville RA; Taylor DM
    Vet Rec; 2006 Mar; 158(11):361-6. PubMed ID: 16547182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII.
    Foster PR; Griffin BD; Bienek C; McIntosh RV; MacGregor IR; Somerville RA; Steele PJ; Reichl HE
    Vox Sang; 2004 Feb; 86(2):92-9. PubMed ID: 15023177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of BSE infectivity on chips of bone by autoclaving during the manufacture of gelatine.
    Grobben AH; Steele PJ; Somerville RA; Taylor DM
    Vet Rec; 2006 Jan; 158(3):94-6. PubMed ID: 16428664
    [No Abstract]   [Full Text] [Related]  

  • 7. Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin.
    Reichl HE; Foster PR; Welch AG; Li Q; MacGregor IR; Somerville RA; Fernie K; Steele PJ; Taylor DM
    Vox Sang; 2002 Aug; 83(2):137-45. PubMed ID: 12201843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BSE control: detection of gelatine-derived peptides in animal feed by mass spectrometry.
    Fernandez Ocaña M; Neubert H; Przyborowska A; Parker R; Bramley P; Halket J; Patel R
    Analyst; 2004 Feb; 129(2):111-5. PubMed ID: 14752552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bovine spongiform encephalopathy agent in a prion protein (PrP)ARR/ARR genotype sheep after peripheral challenge: complete immunohistochemical analysis of disease-associated PrP and transmission studies to ovine-transgenic mice.
    Bencsik A; Baron T
    J Infect Dis; 2007 Apr; 195(7):989-96. PubMed ID: 17330789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of the BSE agent.
    Taylor D
    C R Biol; 2002 Jan; 325(1):75-6. PubMed ID: 11862625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of bovine from porcine gelatines using polyclonal anti-peptide antibodies in indirect and competitive indirect ELISA.
    Venien A; Levieux D
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):418-24. PubMed ID: 15899572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of BSE agent.
    Taylor DM
    Dev Biol Stand; 1991; 75():97-102. PubMed ID: 1794635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the efficacy of hyperbaric rendering procedures in inactivating bovine spongiform encephalopathy (BSE) and scrapie agents.
    Schreuder BE; Geertsma RE; van Keulen LJ; van Asten JA; Enthoven P; Oberthür RC; de Koeijer AA; Osterhaus AD
    Vet Rec; 1998 May; 142(18):474-80. PubMed ID: 9612912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of meat-bone flour in the transmission of bovine spongiform encephalopathy (BSE)].
    Gajecki M
    Przegl Epidemiol; 2001; 55(1 Suppl 2):83-8. PubMed ID: 11496802
    [No Abstract]   [Full Text] [Related]  

  • 15. Highly bovine spongiform encephalopathy-sensitive transgenic mice confirm the essential restriction of infectivity to the nervous system in clinically diseased cattle.
    Buschmann A; Groschup MH
    J Infect Dis; 2005 Sep; 192(5):934-42. PubMed ID: 16088845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of the clearance factor for transmissible spongiform encephalopathy agents during the manufacturing process of polygeline.
    Peano S; Reiner G; Carbonatto M; Bodenbender L; Boland P; Abel KJ
    Intensive Care Med; 2000 May; 26(5):608-12. PubMed ID: 10923737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bovine spongiform encephalopathy (BSE)--infectious, contagious, zoonotic or production disease?
    Doherr MG
    Acta Vet Scand Suppl; 2003; 98():33-42. PubMed ID: 15259778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to investigating transmission of spongiform encephalopathies in domestic animals using BSE as an example.
    Simmons MM; Spiropoulos J; Hawkins SA; Bellworthy SJ; Tongue SC
    Vet Res; 2008; 39(4):34. PubMed ID: 18284911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the impact of cattle testing strategies on human exposure to BSE agents in Japan.
    Tsutsui T; Kasuga F
    Int J Food Microbiol; 2006 Apr; 107(3):256-64. PubMed ID: 16388864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The infectivity of transmissible spongiform encephalopathy agent at low doses: the importance of phospholipid.
    Gale P
    J Appl Microbiol; 2006 Aug; 101(2):261-74. PubMed ID: 16882133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.